RBC Capital Keeps Their Hold Rating on ADC Therapeutics (ADCT)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Leonid Timashev maintained a Hold rating on ADC Therapeutics (ADCT) with a $2.00 price target, as reported on July 7. The stock closed at $1.35. Timashev, a 5-star analyst in the Healthcare sector, contrasts with the broader TipRanks consensus of Moderate Buy and a higher average price target of $5.67.
In a report released on July 7, Leonid Timashev from RBC Capital maintained a Hold rating on ADC Therapeutics, with a price target of $2.00. The company’s shares closed yesterday at $1.35.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Timashev is a 5-star analyst with an average return of 27.7% and a 61.41% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Revolution Medicines, and ADC Therapeutics.
ADC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.67.